Frontier Medicines’ Post

Before going public, #biotech companies typically raise funds through private equity. Here are some less common financial options for biotech companies during the pre-IPO and post-IPO phases. #AskMarcum #biotechfinancing

Before going public, #biotech companies typically raise funds through private equity. Here are some less common financial options for biotech companies during the pre-IPO and post-IPO phases. #AskMarcum #biotechfinancing

Before going public, #biotech companies typically raise funds through private equity. Here are some less common financial options for biotech companies during the pre-IPO and post-IPO phases. #AskMarcum #biotechfinancing

🟠 In the face of continuing global economic uncertainties, it is fantastic to see the exceptional resilience of UK biotechs and the confidence of international investors in our sector. £563 million raised in Q3 is the best result since the record-breaking year of 2021. Read the UK Biotech Financing report to find out more ➡️ https://lnkd.in/ePF2t57a #investinbiotech

Before going public, #biotech companies typically raise funds through private equity. Here are some less common financial options for biotech companies during the pre-IPO and post-IPO phases. #AskMarcum #biotechfinancing

Epoch 28: Raising Money in Biotech? Plan for Longer than Expected 👉 Macro picture crystallizing 👉 Biotech financing vs other industries? 👉 Round sizes under pressure 👉 Time to finance timeline elongating https://lnkd.in/dEkBy2bY

Provaris is pleased to announce that it has secured a two-year $3m standby facility through a Convertible Note with Macquarie Bank: https://loom.ly/Qv_Fw4I The Facility provides additional flexibility and source of cost-effective capital to support Provaris’ forward-looking development program in 2024-2025, including development costs for potential hydrogen production and export sites in the Nordic region, the Prototype Tank program and Final Class approvals, and future working capital requirements for the production and sale of small-scale tanks based on Provaris’ proprietary technology. We are also undertaking a Share Purchase Plan to raise up to $2m (before costs) with the offer supported through a partial underwriting of $1m from existing Institutional and Sophisticated shareholders. Funds raised will be applied to the ongoing hydrogen development activities related to both technical and commercial activities in Europe, and general working capital of the group. Read more: https://loom.ly/ESzLGds

📰Proparco invests €20mn in Amethis Fund III to support African medium-sized enterprises Proparco and Amethis continue their long-standing collaboration in support of the African private sector. This new investment by Proparco in the Amethis Fund III ("AF III") aims to support African medium-sized companies that provide quality goods and services on the continent. Read more: https://lnkd.in/eABmkSS4

Crazy, crazy times in the cannabis industry. Huge, huge potential development & ripple effect from Fed intentions to reschedule from Schedule I to Schedule III. Just what that all means, how it may impact the industry remains to be seen. Including & especially with access to capital/financing. Social equity license holders-their access to capital, their "readiness" to be invested in & financed depends on diligent, thorough preparation & a strong sanity check to their expectations. Here are some "freebies" to help you contemplate the challenges of raising funds in the cannabis space. We can help. #cannabiscapital #cannabisfinancing #cannabisfunding #cannabisinvesting #cannabiscfo #cannabisbanking #cannabislending